Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
The money raised through the Offer for Sale goes to existing investors, not the company.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
KRONOX Lab Sciences Limited manufactures high-purity specialty fine chemicals, including inorganic chemicals, phosphates and metallic chemicals, for a diverse set of end-use industries. Its catalogue spans more than 185 products used mainly by pharmaceutical, research and industrial customers, with sales to customers in India and more than 20 other countries. Incorporated in 2008 and based in Vadodara, Gujarat, the company runs three manufacturing facilities with a combined installed capacity of roughly 7,242 tonnes per annum and employs around 212 people. It serves close to 600 customers and holds what it describes as a near-monopoly position in certain of its products, supported by a long operating history and repeat business from a large share of its client base. Revenue and profit grew steadily across the three fiscal years leading up to the offer. The IPO itself was entirely an offer for sale by the company's three promoter selling shareholders, so no fresh capital was raised by the company, and it competes in a specialty chemicals space that includes other listed manufacturers such as Tatva Chintan, Neogen Chemicals and Sigachi Industries.
Ahead of the offer the company's selling shareholders raised about Rs 39 crore through the anchor book, with participation from funds including Negen Undiscovered Value Fund, Chanakya Opportunities Fund I, Minerva Emerging Opportunities Fund, Capri Global Capital, Moneywise Financial Services and VPK Global Ventures Fund.
Source: RHP • Analysis provided for informational purposes
Last Updated: 14 July 2026, 11:25 PM
Broad, entrenched product range
The company offers over 185 products and holds a near-monopoly position in certain of them, giving it pricing power and durable customer relationships.
High customer retention
A large share of the company's clients are repeat customers, reflecting consistent product quality and reliability in a specialty chemicals niche.
Long operating track record and R&D focus
With operations dating back over a decade and a continued emphasis on research and development, the company has built technical depth across its product lines.
Product quality and standards risk
Any deviation of products from prescribed quality standards could damage customer relationships and financial performance.
Execution risk on capacity expansion
The company's plans to bring new manufacturing capacity online carry execution risk that could affect future growth if delayed or under-delivered.
Concentration in top products
A relatively small number of products account for a majority of revenue, so weaker demand for any of them could disproportionately affect results.
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.